Skip to content
Independent analysis of NHS open data
PharmaInsight

Lercanidipine hydrochloride vs Nifedipine

National NHS prescribing compared (Prescription Cost Analysis)
Data updated April 2026

Lercanidipine hydrochloride was dispensed 3.9× as often as Nifedipine in April 2026 — 418,386 items versus 107,153 in England.

418,386items

Lercanidipine hydrochloride · April 2026

NHSBSA Prescription Cost Analysis

107,153items

Nifedipine · April 2026

NHSBSA Prescription Cost Analysis

Figure 1. Lercanidipine hydrochloride versus Nifedipine: national items dispensed by month

▬ Lercanidipine hydrochloride   ·   ╌ Nifedipine

0 212k 425k Jan 2021 Nov 2021 Sep 2022 Jul 2023 May 2024 Mar 2025 Apr 2026 Nifedipine 418,386 Jan 2021: 236k Feb 2021: 224k Mar 2021: 252k Apr 2021: 245k May 2021: 235k Jun 2021: 251k Jul 2021: 252k Aug 2021: 244k Sep 2021: 253k Oct 2021: 242k Nov 2021: 253k Dec 2021: 268k Jan 2022: 250k Feb 2022: 238k Mar 2022: 270k Apr 2022: 254k May 2022: 268k Jun 2022: 263k Jul 2022: 263k Aug 2022: 273k Sep 2022: 271k Oct 2022: 268k Nov 2022: 276k Dec 2022: 282k Jan 2023: 279k Feb 2023: 260k Mar 2023: 300k Apr 2023: 274k May 2023: 294k Jun 2023: 302k Jul 2023: 294k Aug 2023: 305k Sep 2023: 299k Oct 2023: 304k Nov 2023: 310k Dec 2023: 312k Jan 2024: 321k Feb 2024: 306k Mar 2024: 317k Apr 2024: 330k May 2024: 342k Jun 2024: 321k Jul 2024: 353k Aug 2024: 344k Sep 2024: 336k Oct 2024: 359k Nov 2024: 346k Dec 2024: 360k Jan 2025: 368k Feb 2025: 334k Mar 2025: 362k Apr 2025: 369k May 2025: 386k Jun 2025: 372k Jul 2025: 402k Aug 2025: 372k Sep 2025: 393k Oct 2025: 407k Nov 2025: 378k Dec 2025: 423k Jan 2026: 407k Feb 2026: 378k Mar 2026: 425k Apr 2026: 418k

Source: NHSBSA Prescription Cost Analysis, to April 2026

Lercanidipine hydrochloride versus Nifedipine, April 2026
Measure Lercanidipine hydrochloride Nifedipine
Items, April 2026 418,386 107,153
Items, last 12 months 4,761,081 1,279,286
Net ingredient cost, April 2026 £1,039,977 £1,846,307

See the full profile for Lercanidipine hydrochloride or Nifedipine.